Future of Digital Trust Explored at Upcoming ISACA Conference Europe Featuring Opening Keynote Hannah Fry
Bringing together global industry experts and thought leaders, ISACA Conference Europe, 19-21 October 2022 in Rome and online, will examine the future of digital trust and look at emerging technologies, best practices, and leadership development topics. The hybrid, multi-day event will include a mix of in-person and virtual sessions that will also be available on demand, as well as interactive panel discussions on digital trust and new solutions to the industry’s current challenges.
The conference features more than 50 speakers, with opening keynote Hannah Fry, professor in the Mathematics of Cities at the Centre for Advanced Spatial Analysis at UCL and best-selling author. Other keynote speakers include award-winning author Carissa Véliz, an associate professor at the Institute for Ethics in AI and a fellow at Hertford College, University of Oxford, and Stefan Hyttfors, acclaimed futurist, author and global speaker on disruptive technologies, behavioural change and next-generation leadership.
ISACA Conference Europe offers sessions for professionals in infosec, cybersecurity, IT audit, privacy, governance and risk roles, each 25-75 long and providing the opportunity to earn up to 18 continuing professional education (CPE) credits. The tracks engage in peer-to-peer knowledge exchange across emerging themes such as the crypto ecosystem, third-party risk, privacy regulations, quantum computing, cybersecurity, digitalization, COBIT, and CMMI.
The beta launch of ISACA’s new Digital Trust Ecosystem Framework is unique to the program. Attendees will have early access when it becomes available.
“ISACA Conference Europe brings together digital trust professionals from across Europe with a common goal of sharing their knowledge, experience, challenges, ideas and solutions to explore how to bring their best ideas to life and pursue digital trust in their roles and at their organisations,” said ISACA Chief Global Strategy Officer Chris Dimitriadis. “This conference is our first opportunity to gather face-to-face in Europe since before the pandemic began and our first since we expanded our presence in Europe with an office in Dublin and a new staff team across the continent. We look forward to bringing our professional community together to help them advance in their careers and make an impact in their enterprises.”
ISACA will also host two optional pre-conference workshops for an additional fee, where attendees can earn up to 14 (CPE) credits—the two-day “How to Mature Your Privacy Compliance Program” or one-day “Cyber Supply Chain Risk Management: The Essentials” workshop.
For details and to register for ISACA Conference Europe 2022, visithttps://store.isaca.org/s/community-event?id=a334w000004h7yFAAQ. Companies interested in sponsorship opportunities can contact sponsorship@isaca.org.
About ISACA
ISACA is a global professional association and learning organization with more than 150,000 members who work in information security, governance, assurance, risk and privacy and a presence in 188 countries, including more than 220 chapters. In 2020, ISACA launched One In Tech, a philanthropic foundation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005216/en/
Contact information
Esther Almendros, ealmendros@isaca.org, T: +1 847-660-5777, M: +34 692 669 722
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom